Image courtesy of Procyrion
October 6, 2015 — The novel Aortix device has earned a spot among the diagnostic and therapeutic modalities accepted for presentation in the Interventional Innovation “Shark Tank” Competition at the Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium. The event will be held Tuesday, Oct. 13, in San Francisco, California.
Developed by Procyrion Inc., Aortix is designed to be the first catheter-based circulatory heart pump specifically for New York Heart Association (NYHA) Class III-IVa heart failure patients who are too sick for medication alone, but not sick enough for risky surgical interventions. The small but powerful micro-pump is deployed downstream of the carotid arteries, which has the potential to eliminate major risks associated with thrombotic strokes, and the device is suitable for ambulatory use.
Duke University cardiologist and Procyrion Scientific Advisory Board member Manesh Patel, M.D., will have eight minutes to present the novel booster pump before a unique group of reviewers who will select the best technological concepts of the year. The top three finalists will be selected to answer additional questions from the judges and the winner and first-runner up will be announced Thursday, Oct. 15.
The Aortix device is not approved for use or sale.
For more information: www.procyrion.com
May 13, 2026 
